News
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...
Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...
Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...
Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...
Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results ...
Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...
Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...
U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results